

Cite this: *Chem. Sci.*, 2019, 10, 5815

All publication charges for this article have been paid for by the Royal Society of Chemistry

Leoligin-inspired synthetic lignans with selectivity for cell-type and bioactivity relevant for cardiovascular disease†‡

Thomas Linder, ^a Rongxia Liu, ^b Atanas G. Atanasov, ^b Yuanfang Li, ^b Sophie Geyrhofer,^a Stefan Schwaiger, ^c Hermann Stuppner, ^c Michael Schnürch, ^a Verena M. Dirsch ^b and Marko D. Mihovilovic ^{*a}

Recently, a natural compound leoligin, a furan-type lignan, was discovered as an interesting hit compound with an anti-inflammatory pharmacological activity profile. We developed a modular and stereoselective approach for the synthesis of the edelweiss-derived lignan leoligin and used the synthetic route to rapidly prepare leoligin analogs even on the gram scale. Proof of concept of this approach together with cell-based bio-assays gained structural analogs with increased selectivity towards vascular smooth muscle *versus* endothelial cell proliferation inhibition, a major benefit in fighting vascular neointima formation. In addition, we identified the structural features of leoligin analogs that define their ability to inhibit the pro-inflammatory NF- κ B pathway. Results are discussed in the context of structural modification of these novel synthetic lignans.

Received 25th January 2019

Accepted 22nd April 2019

DOI: 10.1039/c9sc00446g

rsc.li/chemical-science

Introduction

Cardiovascular disease (CVD) is the number one cause of death in the world.¹ Atherosclerosis, along with hypertension, is the main cause of CVD.² Initiation of atherosclerosis is associated with chronic injury of endothelial cells (ECs), followed by the accumulation of lipids and extracellular matrix in the intima, recruitment of monocytes that differentiate into pro-inflammatory macrophage foam cells, and exaggerated proliferation of vascular smooth muscle cells (VSMCs), resulting in neointima formation and arterial lumen loss.³

Severe vascular lumen loss can be treated by cardiovascular interventions including coronary balloon angioplasty, stenting and coronary bypass surgery.⁴ Restenosis, the re-narrowing of

surgically dilated arteries, appears to be a major problem of percutaneous transluminal coronary angioplasty (PTCA) or PTCA in combination with bare-metal stent implantation and occurs as a proliferative and pro-inflammatory response to injury resulting again in neointimal hyperplasia.⁵ An important stimulus for VSMC proliferation is the platelet-derived growth factor (PDGF). While VSMC proliferation promotes restenosis, re-lining of the vessel wall with ECs is desirable.⁶ Hence, re-endothelialization may lower the risk of thrombotic events that are increased by drug-eluting stents and bioresorbable scaffolds.^{4,7,8} Drug-eluting stents release anti-proliferative/immunosuppressant or cytotoxic drugs, such as rapamycin (sirolimus) or related substances and paclitaxel, respectively, to reduce local VSMC proliferation. These drugs, however, also inhibit EC proliferation.^{9–11} Thus, an ideal drug for restenosis treatment should be able to selectively inhibit VSMC proliferation.

Inflammation is an important contributor to the pathogenesis of atherosclerosis and restenosis.¹² Nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B) is a transcription factor that promotes the expression of pro-inflammatory mediators including cytokines such as interleukin (IL)-1 β , tumor necrosis factor (TNF)- α , and IL-6, adhesion molecules, and mediators involved in inflammation and tissue reorganization such as cyclooxygenase (COX)-2 or matrix metalloproteinases.¹³ Due to its central pro-inflammatory action, inhibition of NF- κ B may be a promising pharmacological target in (neo)atherosclerosis and restenosis.^{13,14}

Leoligin **1a** (Fig. 1) is a furan-type lignan and a secondary metabolite found in the roots of edelweiss (*Leontopodium nivale* ssp. *alpinum*).^{15–17} Amongst other effects,^{18–21} it had previously

^aInstitute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163-OC, 1060 Vienna, Austria. E-mail: marko.mihovilovic@tuwien.ac.at

^bDepartment of Pharmacognosy, University of Vienna, Althanstraße 14, 1090 Vienna, Austria. E-mail: verena.dirsch@univie.ac.at

^cInstitute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria

† Dedicated to Prof. Johannes Fröhlich on the occasion of his 60th birthday.

‡ Electronic supplementary information (ESI) available: Synthetic procedures, NMR-spectra of all compounds, and description of pharmacological experiments. See DOI: 10.1039/c9sc00446g

§ Current affiliation: School of Pharmacy, Yantai University, 264005, Yantai, PR China.

¶ Current affiliation: Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, 05-552, Jastrzebiec, Poland.

|| Current affiliation: Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.




Fig. 1 Leoligin, the major lignan isolated from *L. nivale ssp. alpinum*.

been shown to inhibit intimal hyperplasia in a human saphenous vein organ culture model, as well as in a mouse model for vein graft disease.²² The observed effect is based on the inhibition of VSMC proliferation.²² Although not cytotoxic, leoligin also inhibited the proliferation of ECs. In addition, the potency of leoligin was not high enough (VSMC, IC_{50} : 32.1 μ M) for it to be considered a useful tool compound and to study its activities in cardiovascular disease. Since leoligin is exclusively present in the roots of *Leontopodium* spp. at concentrations of 0.0155 and 0.0547 w% in cultivated edelweiss plants (*L. nivale ssp. alpinum* cv. 'Helvetia') and 0.005–0.010 w% in collected samples of the same species, the possibility of production in hairy root cultures was investigated.¹⁷ Since edelweiss is a strongly protected plant, a biosynthetic or purely synthetic pathway producing leoligin is required, where the latter one would also allow the preparation of leoligin derivatives.²³

Results and discussion


In the context of a multi-disciplinary project on the identification of natural products with anti-inflammatory activity,²⁴ developing a fast and high-yield chemical synthesis method for leoligin was our first objective.²⁵ With respect to intimal hyperplasia, the objectives were two-fold: (i) starting out from the natural hit molecule, a synthetic analog was sought with higher potency compared to leoligin, but also a better cell-selectivity with respect to inhibition of cell proliferation (VSMCs *versus* ECs); and (ii) since leoligin appeared to be a moderate NF- κ B inhibitor (IC_{50} : 19.7 μ M), we set out to identify the structural features that define its anti-inflammatory action.

For the preparation of synthetic leoligin analogs (and leoligin itself), it was important to develop a modular synthetic strategy, in order to gain access to a large variety of structural analogs with minimum effort. Recently, synthesis of a structure claimed to be leoligin was published.²⁶ However, all steps were carried out in the absence of a chiral inducer and, additionally, diastereocontrol within the sequence seems highly questionable, in particular as spectral properties of the reported synthetic product do not match with those of the natural product isolate of leoligin (see ESI†).

The stereoselective synthetic route developed by us is outlined in Scheme 1. Key steps of the synthetic strategy involve (i) establishing an enantiomerically pure status upon lipase mediated kinetic resolution; (ii) formation of a tetrahydrofuran ring system upon diastereoselective radical cyclization; (iii) regio- and stereo-selective arylation *via* hydroboration and subsequent Suzuki–Miyaura cross-coupling in a single-operation cascade and, finally, (iv) esterification employing a modified Mitsunobu protocol.

The initial addition of vinylmagnesium bromide to benzaldehyde derivatives **2a–c** is followed by the first key step, a lipase-catalyzed kinetic resolution^{27–31} of *rac*-**3a–c** employing Amano lipase PS. In this case, the stereoselectivity of the enzyme favors esterification of the undesired enantiomer, leaving behind enantiopure (>98% ee) alcohols (*S*)-**3a–c**. Etherification with propargylbromide gave intermediates **4a–c**, paving the way for a standard *m*-CPBA epoxidation to **5a–c**. The final cyclization to **6a–c** was carried out using radical cyclization, which was previously applied by Roy and co-workers for the synthesis of structurally related racemic furan-type lignans (e.g. *rac*-dimethyl lariciresinol).^{32,33} After the individual steps were established, we successfully combined the transformation of **3** into **6** in a single operation, offering the advantage that neither **4** nor **5** had to be isolated but the crude materials could be subjected to the next steps, directly. This provided rapid access to variously substituted compounds **6a–c**.

Intermediate **6** was crucial for a strategy employing maximum flexibility towards focused compound library design, since it would allow access to diversely substituted benzylic



Scheme 1 Synthesis of a library of furan-type lignans based on the leoligin hit-structure.

groups in position three of the THF core upon sequential hydroboration and Suzuki–Miyaura cross-coupling. For that purpose, the hydroxymethyl group in **6** was protected, initially with an acetyl group, to test whether the ester required in the final products could be introduced already at this point. However, we observed an unsatisfactory diastereoselectivity of 82 : 18 in favor of the desired 3,4-*cis* configuration. Since esterification with angelic acid would lead to a trigonal planar geometry of the resulting ester, it was believed that in this case also the steric demand of the ester would be insufficient to guarantee high 3,4-*cis* selectivity. Hence, we switched to silyl protecting groups with tetrahedral geometry and, indeed, enough steric shielding on the bottom face of the molecule was provided when employing the bulky TBDMS group to allow 3,4-*cis* diastereoselective hydroboration (~95 : 5) with commonly used and bulky 9-borabicyclo[3.3.1]nonane (9-BBN) as the reagent. A more detailed explanation of the steric effects leading to good diastereoselectivity can be found in the ESI†. The corresponding intermediate could be converted *in situ* with aryl bromides or iodides *via* Suzuki–Miyaura coupling to the arylated products.³⁴ Furthermore, even TBDMS deprotection could be carried out *in situ* affording products **7a–h** in 94 : 6 to 97 : 3 d.r. (typically in 50 to 70% yield over 4 steps) without isolation of any intermediate. The introduced (hetero)aryl moieties cover a wide range of electron-rich and electron-deficient residues important for systematic biological evaluation (see ESI† for Experimental details).

The synthesis of leoligin and its derivatives was completed by simple esterification to **1a–l** with various saturated, unsaturated and (hetero)aromatic acyl residues, either *via* a standard Steglich reaction³⁵ or *via* a Mitsunobu protocol (employing the more easily removable ADDP reagent).^{36,37} The latter had to be applied for the preparation of the parent leoligin and all other compounds containing the angelic acid ester moiety to avoid double bond isomerization which occurred otherwise upon EDCI-mediated acid activation and reversible Michael addition by the 4-DMAP acylation catalyst.³⁸

Overall, our synthetic route was successfully employed to obtain leoligin on a gram-scale with matching NMR signals and physical properties compared with the natural compound isolate (see ESI†), hence, unambiguously confirming the relative and absolute stereochemistry of the natural compound by total synthesis. Moreover, we could rapidly synthesize tailor made analogs to probe the structure–activity relationship within more elaborate pharmacological profiling. In these examples, modifications were made at three different positions: (i) variation of the substitution pattern of the aryl group in position 2; (ii) variation of the substitution pattern of the benzylic arene in position 4; and (iii) variation of the ester functionality.

In the first round, we screened a set of compounds with different ester functionalities for NF-κB and VSMC inhibitory action at a single dose (20 μM), which is close to the IC₅₀ of leoligin for NF-κB (19.7 μM) and VSMC (32.1 μM) inhibition. For this, we used HEK-293/NF-κB-luc cells containing a NF-κB-driven luciferase reporter gene and PDGF-activated rat aortic VSMCs, respectively, to identify promising candidates, which

were then subjected to dose–response studies (see ESI† for details on all cell-based assays). We discovered that the NF-κB-inhibitory activity is very susceptible to the acyl moiety; for instance, compound **1b** (Fig. 2), which differs from leoligin only in the shift of one methyl group on the α,β-unsaturated system, had a much more suppressive effect on NF-κB activation, whereas VSMC proliferation inhibition remained unaffected. It was hypothesized that this might be due to the significantly reduced Michael-acceptor properties (which were problematic already in the esterification reactions) of the modified ester due to increased steric shielding of the β-carbon. Hence, saturated alkyl esters should show similar NF-κB inhibition, which was initially supported by compound **1c**, which showed a similarly strong inhibition to **1b** but still no effect on VSMCs. Increasing the steric bulk in the ester functionality led to an even higher activity as in compounds **1d** (IC₅₀ = 2.2 μM) and **1e** (IC₅₀ = 1.6 μM), the latter one reaching the potency of the positive control parthenolide (IC₅₀ = 1.7 μM), a sesquiterpene lactone from feverfew of which the orally bioavailable analog, dimethylamino-parthenolide, reached clinical trials.³⁹ Besides the improved potency for NF-κB inhibition it is of additional importance that compound **1d** also shows VSMC proliferation inhibition for the first time, even though not very pronounced (IC₅₀ = 24.3 μM). This effect is further increased in compound **1e** (IC₅₀ = 10.3 μM). Other ester modifications did not further increase the potency for VSMC proliferation inhibition. It has to




Fig. 2 Development of leoligin analogs as NF-κB inhibitors. NF-κB inhibition is expressed by their IC₅₀ values. Inhibition of EC proliferation is given as the reduction in cell number ± standard error of the mean at 30 μM concentration with respect to the negative control (100%).



be mentioned that all tested compounds so far also impaired EC proliferation. Hence, further investigation on compounds with increased selectivity for inhibiting VSMC proliferation *versus* ECs was necessary.

Again, we first screened at a single dose (30 μM), close to the IC_{50} of leoligin (32.1 μM) for inhibition of VSMC proliferation.

Here it turned out that modifications in the benzylic arene were crucial for obtaining the desired activity. In an initial screening it was observed that *p*-*tert*-butyl bearing alcoholic compound **7b** was already much more active on these cells compared to leoligin, while being inactive on NF- κB (Fig. 3).

This was interesting because the analog leoligin alcohol (dimethyl lariciresinol) and most of the screened compounds devoid of an acyl group did not show any appreciable VSMC proliferation inhibition (data not shown). Consequently, attaching the angelic acid scaffold also present in leoligin should result in even higher potency. Indeed, we found that the corresponding compound **1f** was about ten times more active than the natural product (IC_{50} : 3.2 μM), however **1f** also showed undesired VSMC toxicity (Fig. 3).

When screening compounds with different substitution patterns on the C2-aryl ring, compound **1g** in which the 3,4-dimethoxy groups were replaced with *p*-fluorine showed an activity profile in favor of VSMC proliferation inhibition, and we expected a synergistic effect by combining these two modifications as in compound **1h**. This did not turn out to be the case, but surprisingly, no effect on EC proliferation of **1h** was observed at 30 μM (contrary to **7b**, **1f** and leoligin), which was precisely the desired profile (Fig. 3). To our dismay, however, a subsequent cytotoxicity study measuring cellular lactate

dehydrogenase (LDH) release showed that this compound was significantly toxic to VSMCs (at a concentration of 30 μM) indicating that necrosis and/or apoptosis had occurred. Thus, this issue had to be addressed next.

Since we had shown that the desired VSMC/EC selectivity profile can be achieved by modifications of the aryl moieties, a second series of such compounds was synthesized and subjected to an activity screening. Since VSMC toxicity always occurred in the presence of a *tert*-butyl group on the benzylic arene, this motif was now avoided. In this screening, compound **1i** (Fig. 4) showed some preference for the inhibition of VSMC proliferation *vs.* the inhibition of NF- κB activity while toxicity was not encountered, although the overall potency was considerably lower. To improve the potency, it was envisioned to combine the structural variations of compounds **1i** and previously discussed compound **1g**, with the aim to attain a potent compound without VSMC toxicity. The corresponding compound **1j** was synthesized and indeed it proved to be the most active analog, so far (VSMC: IC_{50} : 1.9 μM), while no inhibition of NF- κB or EC proliferation was observed, and no cytotoxicity was found. Compounds with similar modifications on the two arene rings were tested as well (*e.g.* **1k** and **1l**, Fig. 4), showing the same activity profile and establishing this interesting chemotype as a lead for future optimizations. Although an IC_{50} of 1.9 μM does not match the potency of compounds in use, such as paclitaxel that reaches an IC_{50} of 108 nM in our system, **1j** showed higher selectivity towards VSMCs *versus* ECs,⁴⁰ which was one important goal of this study.




Fig. 3 Development of leoligin analogs as inhibitors of VSMC proliferation. Inhibition of VSMC proliferation is expressed by their IC_{50} values. Inhibition of EC proliferation is given as the reduction in the number of cells \pm standard error of the mean at 30 μM concentration with respect to the negative control (100%). VSMC toxicity was also tested (*via* LDH release) at 30 μM concentration; for simplicity, significant positive toxicity ($p < 0.1$ in one-tailed *t*-test) is described qualitatively with respect to the negative control.




Fig. 4 Further development of NF- κB - and VSMC-selective inhibitors.



Conclusions

In conclusion, we succeeded in establishing the first total synthesis of leoligin in a stereoselective fashion on a gram-scale. Furthermore, we could show that, based on chemistry that allowed mid- and late-stage incorporation to replace moieties pertinent to the tetrahydrofuran core of leoligin, the phenotype-based activity profile of this natural product can be individualized and selective tool compounds for investigations of its pharmacology can be obtained. Specifically, compounds which selectively inhibit VSMC proliferation or suppress the NF- κ B pathway were obtained by a rational design approach. This allows further elaboration of this natural product hit compound towards an interesting pharmacological tool with potential as a lead towards drug development.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This project was supported in part by the Austrian Science Fund (FWF): S10710 and S10704 (NFN 'Drugs from Nature Targeting Inflammation'). The contributions of Diyana Ogurlu and Natalie Maier-Reveredo to technical work are gratefully acknowledged.

Notes and references

- 1 C. D. Mathers and D. Loncar, *PLoS Med.*, 2006, **3**, e442.
- 2 I. F. Charo and R. Taub, *Nat. Rev. Drug Discovery*, 2011, **10**, 365.
- 3 K. Wadey, J. Lopes, M. Bendeck and S. George, *Cardiovasc. Res.*, 2018, **114**, 601–610.
- 4 R. A. Byrne, G. W. Stone, J. Ormiston and A. Kastrati, *Lancet*, 2017, **390**, 781–792.
- 5 B. Mills, T. Robb and D. F. Larson, *Perfusion*, 2012, **27**, 520–528.
- 6 B. E. Claessen, J. P. S. Henriques, F. A. Jaffer, R. Mehran, J. J. Piek and G. D. Dangas, *J. Am. Coll. Cardiol.*, 2014, **7**, 1081–1092.
- 7 A. Colombo, F. Giannini and C. Briguori, *J. Am. Coll. Cardiol.*, 2017, **70**, 607–619.
- 8 Y. Sotomi, Y. Onuma, C. Collet, E. Tenekecioglu, R. Virmani, S. Kleiman Neal and W. Serruys Patrick, *Circ. Res.*, 2017, **120**, 1341–1352.
- 9 A. I. McDonald and M. L. Iruela-Arispe, *Vasc. Pharmacol.*, 2015, **72**, 9–15.
- 10 K. Korybalska, E. Kawka, A. Breborowicz and J. Witowski, *J. Physiol. Pharmacol.*, 2017, **68**, 397–405.
- 11 D.-H. Lee and J. M. de la Torre Hernandez, *Eur. Cardiol.*, 2018, **13**, 54–59.
- 12 K. Toutouzas, A. Colombo and C. Stefanadis, *Eur. Heart J.*, 2004, **25**, 1679–1687.
- 13 J. Dabek, A. Kulach and Z. Gasior, *Pharmacol. Rep.*, 2010, **62**, 778–783.
- 14 B. Pamukcu, G. Y. H. Lip and E. Shantsila, *Thromb. Res.*, 2011, **128**, 117–123.
- 15 M. J. Dobner, E. P. Ellmerer, S. Schwaiger, O. Batsugkh, S. Narantuya, M. Stütz and H. Stuppner, *Helv. Chim. Acta*, 2003, **86**, 733–738.
- 16 M. J. Dobner, S. Sosa, S. Schwaiger, G. Altinier, R. Della Loggia, N. C. Kaneider and H. Stuppner, *Planta Med.*, 2004, **70**, 502–508.
- 17 C. Wawrosch, S. Schwaiger, H. Stuppner and B. Kopp, *Fitoterapia*, 2014, **97**, 219–223.
- 18 L. Wang, A. Ladurner, S. Latkolik, S. Schwaiger, T. Linder, J. Hosek, V. Palme, N. Schilcher, O. Polansky, E. H. Heiss, H. Stangl, M. D. Mihovilovic, H. Stuppner, V. M. Dirsch and A. G. Atanasov, *J. Nat. Prod.*, 2016, **79**, 1651–1657.
- 19 B. Scharinger, B. Messner, A. Tuerkcan, D. Schuster, A. Vuorinen, F. Pitterl, K. Heinz, K. Arnhard, G. Laufer, M. Grimm, H. Stuppner, H. Oberacher, P. Eller, A. Ritsch and D. Bernhard, *J. Mol. Cell. Cardiol.*, 2016, **99**, 35–46.
- 20 K. Duwensee, S. Schwaiger, I. Tancevski, K. Eller, M. van Eck, P. Markt, T. Linder, U. Stanzl, A. Ritsch, J. R. Patsch, D. Schuster, H. Stuppner, D. Bernhard and P. Eller, *Atherosclerosis*, 2011, **219**, 109–115.
- 21 S. Schwaiger, M. Adams, C. Seger, E. P. Ellmerer, R. Bauer and H. Stuppner, *Planta Med.*, 2004, **70**, 978–985.
- 22 U. Reisinger, S. Schwaiger, I. Zeller, B. Messner, R. Stigler, D. Wiedemann, T. Mayr, C. Seger, T. Schachner, V. M. Dirsch, A. M. Vollmar, J. O. Bonatti, H. Stuppner, G. Laufer and D. Bernhard, *Cardiovasc. Res.*, 2009, **82**, 542–549.
- 23 A. G. Atanasov, B. Waltenberger, E.-M. Pferschy-Wenzig, T. Linder, C. Wawrosch, P. Uhrin, V. Temml, L. Wang, S. Schwaiger, E. H. Heiss, J. M. Rollinger, D. Schuster, J. M. Breuss, V. Bochkov, M. D. Mihovilovic, B. Kopp, R. Bauer, V. M. Dirsch and H. Stuppner, *Biotechnol. Adv.*, 2015, **33**, 1582–1614.
- 24 B. Waltenberger, A. G. Atanasov, E. H. Heiss, D. Bernhard, J. M. Rollinger, J. M. Breuss, D. Schuster, R. Bauer, B. Kopp, C. Franz, V. Bochkov, M. D. Mihovilovic, V. M. Dirsch and H. Stuppner, *Monatsh. Chem.*, 2016, **147**, 479–491.
- 25 T. Linder, M. Schnürch and M. D. Mihovilovic, *Targets Heterocycl. Syst.*, 2015, **19**, 274–298.
- 26 Y. Xia, L. Zou, J. Zhang and W. Zhang, *J. Chem. Res.*, 2018, **42**, 350–353.
- 27 W. S. Qayed, A. S. Aboraia, H. M. Abdel-Rahman and A. F. Youssef, *J. Chem. Pharm. Res.*, 2015, **7**, 311–322.
- 28 U. Bornscheuer and R. Kazlauskas, *Hydrolases in Organic Synthesis: Regio- or Stereoselective Biotransformations*, Wiley, 1999.
- 29 A. Ghanem and H. Y. Aboul-Enein, *Chirality*, 2005, **17**, 1–15.
- 30 P. Chen and P. Xiang, *Tetrahedron Lett.*, 2011, **52**, 5758–5760.
- 31 X. Fu and K. L. Parkin, *J. Am. Oil Chem. Soc.*, 2004, **81**, 45.
- 32 P. K. Mandal, G. Maiti and S. C. Roy, *J. Org. Chem.*, 1998, **63**, 2829–2834.
- 33 T. V. RajanBabu and W. A. Nugent, *J. Am. Chem. Soc.*, 1994, **116**, 986–997.



- 34 C.-H. Chen, Y.-K. Chen and C.-K. Sha, *Org. Lett.*, 2010, **12**, 1377–1379.
- 35 B. Neises and W. Steglich, *Angew. Chem., Int. Ed.*, 1978, **17**, 522–524.
- 36 O. Mitsunobu, *Synthesis*, 1981, **1981**, 1–28.
- 37 K. C. K. Swamy, N. N. B. Kumar, E. Balaraman and K. V. P. P. Kumar, *Chem. Rev.*, 2009, **109**, 2551–2651.
- 38 X. Liang, G. Grue-Sørensen, A. K. Petersen and T. Högberg, *Synlett*, 2012, **23**, 2647–2652.
- 39 A. Ghantous, A. Sinjab, Z. Herceg and N. Darwiche, *Drug Discovery Today*, 2013, **18**, 894–905.
- 40 R. Liu, E. H. Heiss, N. Sider, A. Schinkovitz, B. Gröblacher, D. Guo, F. Bucar, R. Bauer, V. M. Dirsch and A. G. Atanasov, *Mol. Nutr. Food Res.*, 2015, **59**, 843–852.

